Leonard Schleifer

Latest Headlines

Latest Headlines

Regeneron's Schleifer hits the $1B mark, but his biotech is just getting started

After 25 years at the helm of one of biotech's best-case scenarios, Regeneron CEO Leonard Schleifer has crossed the $1 billion threshold, according to Forbes, thanks largely to the company's blockbuster eye drug. And, with a stable of promising late-stage treatments waiting in the wings, the Tarrytown, NY, executive's most profitable work may still be ahead of him.

After Eylea win, Regeneron execs puzzle over R&D scale-up challenge

With a new blockbuster drug and more potential hits in development, Regeneron Pharmaceuticals has been successful long enough for top executives to consider the challenges of keeping the entrepreneurial culture behind the R&D streak alive. Read more >>

The 25 most influential people in biopharma today- 2013

Who in this business hasn't seen billions incinerated in pursuit of sheer folly? Influential today is the savvy executive who can marshal experts as well as financial resources in pursuit of a smarter, better, faster way to develop and market important new drugs. And intelligent research strategies are far more rare than we acknowledge. You'll find some here in our second annual report on the 25 most influential people in the industry (find last year's report here). Check out the list >>